Carcinoma of the urinary bladder in patients receiving cyclophosphamide
about
Adherence to safe handling guidelines by healthcare workers who administer antineoplastic drugsCyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefitChanges produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer.The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up.Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasiaHigh-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease.Problems with immunosuppressive agents in renal diseaseCombination therapy: the risks of infection and tumor induction.Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors.Systemic lupus erythematosus with nephritisReversible papillary hyperplasia of the rat urinary bladderIatrogenic changes in the urinary tract.Urological implications of cyclophosphamide and ifosfamide.Diagnostically challenging cases: what are atypia and dysplasia?A critical review of the literature on acrolein toxicity.Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine.The role of continuous infusion loop diuretics.The case of the edematous bladder.Cyclophosphamide and the urinary tract.Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs.
P2860
Q23914321-56F020A1-D90F-41A2-9583-52E4A9FFE73AQ28367310-8105D784-BE42-4087-AFED-5FAAFC15484AQ30713680-9999DF32-1997-4112-9804-21847C129F7FQ33554543-AA19BF03-750D-4FE4-A7B2-E46FB8ED952BQ33620088-68499672-8908-414D-ACE4-5A63EDAA5E31Q33648083-B916797A-10F6-4168-8793-B11929468669Q34302895-E26F367D-C454-453C-841C-6F886C489FB7Q34309757-E6653F10-688A-423E-BFCE-6DAA07E06ABBQ34341069-C3C82EDD-8604-459D-9899-3C9E7354329BQ35115277-F673BA21-251C-4788-A2AA-C4978523A1C0Q36058467-82CB8C7B-E51D-46DA-BB59-6063957D8539Q36222426-8E6A698B-8C00-462F-92D3-FA7E7D569AC0Q37264407-FA817591-D03B-4EEF-AAAF-CB23B95BACACQ37577983-9C73C65A-902B-4F61-A5A2-01FF248C61D9Q38591485-A1B84783-4026-436B-9404-51AC134A0717Q41117952-B6C1DD12-87C9-4897-AF73-8390F4F026C0Q41142594-D7068045-32FB-41C9-A010-3C0201CD8B79Q41807274-6E51B810-F98F-40C0-B91D-D0964975D559Q44009974-1512EDC5-FA39-4449-AD87-5FB60D562602Q55652491-434DC9AB-24CF-4BD8-83EE-B8EFF47A246C
P2860
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
description
1975 nî lūn-bûn
@nan
1975 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1975 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
name
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@ast
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@en
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@nl
type
label
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@ast
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@en
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@nl
prefLabel
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@ast
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@en
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@nl
P1476
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
@en
P2093
P356
10.1056/NEJM197508072930604
P407
P577
1975-08-07T00:00:00Z